|Bid||0.0000 x 1800|
|Ask||0.0000 x 900|
|Day's Range||2.8800 - 3.0500|
|52 Week Range||2.6400 - 11.0400|
|Beta (5Y Monthly)||0.27|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for CNCELearn more
LEXINGTON, Mass., January 04, 2022--Concert completed patient enrollment in the CTP-543 THRIVE-AA2 Phase 3 trial for alopecia areata.
LEXINGTON, Mass., January 03, 2022--Concert to Participate in the H.C. Wainwright BIOCONNECT Conference.
LEXINGTON, Mass., November 11, 2021--Concert's on-demand fireside chat at the Jefferies London conference will be available beginning at 8:00 a.m. GMT on November 18, 2021.